Haohua Teng1, Chunyu Ji2, Jizhuang Luo3, Bowen Ding4, Alessio Campisi3,5, Tangbing Chen3. 1. Department of Pathology, School of Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 West Huaihai Rd, Xuhui District, Shanghai, 200030, China. tenghh@live.cn. 2. Department of Thoracic Surgery, School of Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 West Huaihai Rd, Xuhui District, Shanghai, 200030, China. 13601870843@163.com. 3. Department of Thoracic Surgery, School of Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 West Huaihai Rd, Xuhui District, Shanghai, 200030, China. 4. Department of Pathology, School of Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 West Huaihai Rd, Xuhui District, Shanghai, 200030, China. 5. Department of Thoracic Surgery, University and Hospital Trust-Ospedale Borgo Trento, piazzale aristide stefani 1, Verona, Italy.
Abstract
PURPOSE: SMARCA4-deficient thoracic tumors are rapid aggressive malignancies, often diagnosed at an advanced and inoperable stage. The value of pulmonary resection for resectable SMARCA4-deficient thoracic tumors is largely unknown. METHODS: In this observational study, we included 45 patients who received surgery for stage I-III SMARCA4-deficient tumors. We compared the molecular, clinicopathological characteristics and survival between SMARCA4-dNSCLC and SMARCA4-deficient undifferentiated tumor (SMARCA4-dUT) patients. RESULTS: Thirty-four SMARCA4-dNSCLC and 11 SMARCA4-dUT patients were included in this study. Molecular profiles were available in 33 out of 45 patients. The most common mutated gene was TP53 (21, 64%), and followed by STK11 (9, 27%), KRAS (5, 15%), FGFR1 (4, 12%) and ROS1 (4, 12%). There were 3 patients that harbored ALK mutation including 1 EML4-ALK rearrangement. There were 2 patients that harbored EGFR rare site missense mutation. SMARCA4-dUT patients had significance worse TTP (HR = 4.35 95% CI 1.77-10.71, p = 0.001) and OS (HR = 4.27, 95% CI 1.12-16.35, p = 0.022) compared to SMARCA4-dNSCLC patients. SMARCA4-dUT histologic type, stage II/III, R1/2 resection and lymphovascular invasion were independent poor prognostic predictors for both TTP and OS. There were 8 patients who received immunotherapy, the objective response rate was 50%. The SMARCA4-dNSCLC patient with ALK rearrangement was treated with crizotinib as second-line therapy, and achieved stable disease for 9.7 months. CONCLUSION: Patients with SMARCA4-deficient tumors have a high probability of early recurrence after surgery, except for stage I patients. Immunotherapy seems to be a valuable strategy to treat recurrence.
PURPOSE: SMARCA4-deficient thoracic tumors are rapid aggressive malignancies, often diagnosed at an advanced and inoperable stage. The value of pulmonary resection for resectable SMARCA4-deficient thoracic tumors is largely unknown. METHODS: In this observational study, we included 45 patients who received surgery for stage I-III SMARCA4-deficient tumors. We compared the molecular, clinicopathological characteristics and survival between SMARCA4-dNSCLC and SMARCA4-deficient undifferentiated tumor (SMARCA4-dUT) patients. RESULTS: Thirty-four SMARCA4-dNSCLC and 11 SMARCA4-dUT patients were included in this study. Molecular profiles were available in 33 out of 45 patients. The most common mutated gene was TP53 (21, 64%), and followed by STK11 (9, 27%), KRAS (5, 15%), FGFR1 (4, 12%) and ROS1 (4, 12%). There were 3 patients that harbored ALK mutation including 1 EML4-ALK rearrangement. There were 2 patients that harbored EGFR rare site missense mutation. SMARCA4-dUT patients had significance worse TTP (HR = 4.35 95% CI 1.77-10.71, p = 0.001) and OS (HR = 4.27, 95% CI 1.12-16.35, p = 0.022) compared to SMARCA4-dNSCLC patients. SMARCA4-dUT histologic type, stage II/III, R1/2 resection and lymphovascular invasion were independent poor prognostic predictors for both TTP and OS. There were 8 patients who received immunotherapy, the objective response rate was 50%. The SMARCA4-dNSCLC patient with ALK rearrangement was treated with crizotinib as second-line therapy, and achieved stable disease for 9.7 months. CONCLUSION: Patients with SMARCA4-deficient tumors have a high probability of early recurrence after surgery, except for stage I patients. Immunotherapy seems to be a valuable strategy to treat recurrence.
Authors: Amandine Crombé; Nicolas Alberti; Nicolas Villard; Frank Pilleul; Xavier Buy; François Le Loarer; Michèle Kind Journal: Eur Radiol Date: 2019-02-14 Impact factor: 5.315
Authors: Nathan M Mollberg; Carrie Bennette; Eric Howell; Leah Backhus; Beth Devine; Mark K Ferguson Journal: Ann Thorac Surg Date: 2014-01-11 Impact factor: 4.330
Authors: Richard C Centore; Gabriel J Sandoval; Luis Miguel Mendes Soares; Cigall Kadoch; Ho Man Chan Journal: Trends Genet Date: 2020-08-29 Impact factor: 11.639
Authors: Francois Le Loarer; Sarah Watson; Gaelle Pierron; Vincent Thomas de Montpreville; Stelly Ballet; Nelly Firmin; Aurelie Auguste; Daniel Pissaloux; Sandrine Boyault; Sandrine Paindavoine; Pierre Joseph Dechelotte; Benjamin Besse; Jean Michel Vignaud; Marie Brevet; Elie Fadel; Wilfrid Richer; Isabelle Treilleux; Julien Masliah-Planchon; Mojgan Devouassoux-Shisheboran; Gerard Zalcman; Yves Allory; Franck Bourdeaut; Francoise Thivolet-Bejui; Dominique Ranchere-Vince; Nicolas Girard; Sylvie Lantuejoul; Francoise Galateau-Sallé; Jean Michel Coindre; Alexandra Leary; Olivier Delattre; Jean Yves Blay; Franck Tirode Journal: Nat Genet Date: 2015-09-07 Impact factor: 38.330
Authors: Liang Liu; Tamjeed Ahmed; William J Petty; Stefan Grant; Jimmy Ruiz; Thomas W Lycan; Umit Topaloglu; Ping-Chieh Chou; Lance D Miller; Gregory A Hawkins; Martha A Alexander-Miller; Stacey S O'Neill; Bayard L Powell; Ralph B D'Agostino; Reginald F Munden; Boris Pasche; Wei Zhang Journal: Mol Oncol Date: 2020-12-17 Impact factor: 7.449